Leticia Kawano-Dourado1, Tracy J Doyle2, Karina Bonfiglioli3, Márcio V Y Sawamura4, Renato H Nakagawa5, Fábio E Arimura6, Hye J Lee4, Diana Arrais de Souza Rangel6, Cleonice Bueno4, Carlos R R Carvalho6, Maria Laura Sabbag7, Camila Molina7, Ivan O Rosas2, Ronaldo A Kairalla6. 1. Pulmonary Division, Hospital das Clinicas HCFMUSP, Medical School, University of Sao Paulo, São Paulo, Brazil; Research Institute, Hospital do Coração (HCor), São Paulo, Brazil. Electronic address: ldourado@hcor.com.br. 2. Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 3. Heart Institute (InCor), the Division of Rheumatology, Hospital das Clinicas HCFMUSP, Medical School, University of Sao Paulo, São Paulo, Brazil. 4. Division of Radiology, Hospital das Clinicas HCFMUSP, Medical School, University of Sao Paulo, São Paulo, Brazil. 5. Research Institute, Hospital do Coração (HCor), São Paulo, Brazil. 6. Pulmonary Division, Hospital das Clinicas HCFMUSP, Medical School, University of Sao Paulo, São Paulo, Brazil. 7. Centro Universitário São Camilo-São Paulo, São Paulo, Brazil.
Abstract
BACKGROUND: Interstitial lung abnormalities (ILA) and interstitial lung disease (ILD) are seen in up to 60% of individuals with rheumatoid arthritis (RA), some of which will progress to have a significant impact on morbidity and mortality rates. Better characterization of progressive interstitial changes and identification of risk factors that are associated with progression may enable earlier intervention and improved outcomes. RESEARCH QUESTION: What are baseline characteristics associated with RA-ILD progression? STUDY DESIGN AND METHODS: We performed a retrospective study in which all clinically indicated CT chest scans in adult individuals with RA from 2014 to 2016 were evaluated for interstitial changes, and the data were further subdivided into ILA and ILD based on clinical record review. Progression was determined visually and subsequently semiquantified. RESULTS: Those individuals with a spectrum of interstitial changes (64 of 293) were older male smokers and less likely to be receiving biologics/small molecule disease-modifying antirheumatic drugs. Of 44% of the individuals with ILA, 46% had had chest CT scans performed for nonpulmonary indications. Of the 56 individuals with ILA/ILD with sequential CT scans, 38% had evidence of radiologic progression over 4.4 years; 29% of of individuals with ILA progressed. Risk factors for progressive ILA/ILD included a subpleural distribution and higher baseline involvement. INTERPRETATION: Of 293 individuals with RA with clinically indicated CT scans, interstitial changes were observed in 22%, one-half of whom had had a respiratory complaint at the time of imaging; radiologic progression was seen in 38%. Of individuals with progressive ILA, one-half had had baseline CT scans performed for nonpulmonary indications. Subpleural distribution and higher baseline ILA/ILD extent were risk factors associated with progression. Prospective longitudinal studies of RA-ILA are necessary.
BACKGROUND: Interstitial lung abnormalities (ILA) and interstitial lung disease (ILD) are seen in up to 60% of individuals with rheumatoid arthritis (RA), some of which will progress to have a significant impact on morbidity and mortality rates. Better characterization of progressive interstitial changes and identification of risk factors that are associated with progression may enable earlier intervention and improved outcomes. RESEARCH QUESTION: What are baseline characteristics associated with RA-ILD progression? STUDY DESIGN AND METHODS: We performed a retrospective study in which all clinically indicated CT chest scans in adult individuals with RA from 2014 to 2016 were evaluated for interstitial changes, and the data were further subdivided into ILA and ILD based on clinical record review. Progression was determined visually and subsequently semiquantified. RESULTS: Those individuals with a spectrum of interstitial changes (64 of 293) were older male smokers and less likely to be receiving biologics/small molecule disease-modifying antirheumatic drugs. Of 44% of the individuals with ILA, 46% had had chest CT scans performed for nonpulmonary indications. Of the 56 individuals with ILA/ILD with sequential CT scans, 38% had evidence of radiologic progression over 4.4 years; 29% of of individuals with ILA progressed. Risk factors for progressive ILA/ILD included a subpleural distribution and higher baseline involvement. INTERPRETATION: Of 293 individuals with RA with clinically indicated CT scans, interstitial changes were observed in 22%, one-half of whom had had a respiratory complaint at the time of imaging; radiologic progression was seen in 38%. Of individuals with progressive ILA, one-half had had baseline CT scans performed for nonpulmonary indications. Subpleural distribution and higher baseline ILA/ILD extent were risk factors associated with progression. Prospective longitudinal studies of RA-ILA are necessary.
Authors: Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake Journal: Am J Respir Crit Care Med Date: 2019-07-15 Impact factor: 21.405
Authors: Tracy J Doyle; George R Washko; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; Miguel J Divo; Bartolome R Celli; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas; Gary M Hunninghake Journal: Am J Respir Crit Care Med Date: 2012-01-20 Impact factor: 21.405
Authors: Joo Hun Park; Dong Soon Kim; I-Nae Park; Se Jin Jang; Masanori Kitaichi; Andrew G Nicholson; Thomas V Colby Journal: Am J Respir Crit Care Med Date: 2007-01-11 Impact factor: 21.405
Authors: George R Washko; David A Lynch; Shin Matsuoka; James C Ross; Shigeaki Umeoka; Alejandro Diaz; Frank C Sciurba; Gary M Hunninghake; Raúl San José Estépar; Edwin K Silverman; Ivan O Rosas; Hiroto Hatabu Journal: Acad Radiol Date: 2009-09-24 Impact factor: 3.173
Authors: Tracy J Doyle; Joyce S Lee; Paul F Dellaripa; James A Lederer; Eric L Matteson; Aryeh Fischer; Dana P Ascherman; Marilyn K Glassberg; Jay H Ryu; Sonye K Danoff; Kevin K Brown; Harold R Collard; Ivan O Rosas Journal: Chest Date: 2014-03-01 Impact factor: 9.410
Authors: Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake Journal: JAMA Date: 2016-02-16 Impact factor: 56.272
Authors: Deborah Assayag; Molly Lubin; Joyce S Lee; Talmadge E King; Harold R Collard; Christopher J Ryerson Journal: Respirology Date: 2013-12-26 Impact factor: 6.424
Authors: Bilal F Samhouri; Robert Vassallo; Sara J Achenbach; Vanessa L Kronzer; John M Davis; Elena Myasoedova; Cynthia S Crowson Journal: Arthritis Care Res (Hoboken) Date: 2022-01-07 Impact factor: 5.178
Authors: Francisco Paulin; Anastasia Secco; Federico Benavidez; Juan José Rodríguez Moncalvo; Orlando Gabriel Carballo; Fernanda Ingenito; Martin Eduardo Fernández; Agustina Cáceres; Fabian Caro; Patricia Sasaki; María Laura Alberti; Paola Orausclio; Augusto Riopedre; Santiago Rossi; María Celina de la Vega Journal: Adv Rheumatol Date: 2021-08-24
Authors: Scott M Matson; Kevin D Deane; Anna L Peljto; Tami J Bang; Peter B Sachs; Avram D Walts; Christopher Collora; Shuyu Ye; M Kristen Demoruelle; Stephen M Humphries; David A Schwartz; Joyce S Lee Journal: Am J Respir Crit Care Med Date: 2022-02-15 Impact factor: 30.528